Movement Alert|Revolution Medicines, Inc. Intraday Rise 4.21% in Regular Trading, Updated Rasonque clinical data lifted sentiment

Market Focus
11/20

On November 20, Revolution Medicines, Inc. posted an Intraday Rise of 4.21% in Regular Trading, trading at $167.56/share, with turnover of $163.0 million.

The move was closely tied to updated Phase 1/2 data for Rasonque plus chemotherapy in previously untreated metastatic pancreatic cancer, where the company reported a 60.7% objective response rate and durable tumor responses, with safety consistent with prior observations.

The update also reinforced the rationale for the ongoing Phase 3 RASolute 303 study. As added context, the company had just received European Commission approval for Rasonque as a monotherapy for metastatic pancreatic adenocarcinoma across EU and EEA markets, based on a Phase 3 trial that met all primary and key secondary endpoints, supporting investor expectations for broader commercialization and indication expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10